StockData
Rapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. (RAPP) company profile

RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$26.15+0.30 (+1.16%)

Close on Nov 13, 2026Market cap $1.25BP/E –Yield –

About Rapport Therapeutics

Pharmaceutical Preparations, SIC 2834

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule precision medicines for patients with neurological and psychiatric disorders. The company utilizes a receptor-associated protein platform to target specific neuronal receptor assemblies. Its lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator in development for drug-resistant focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. In addition, the firm advances discovery-stage nicotinic acetylcholine receptor programs, including RAP-641 for chronic pain and migraine, alongside therapies for hearing and vestibular disorders. Its patient population comprises individuals affected by serious central nervous system and sensory conditions.

The company maintains its corporate headquarters in Boston, Massachusetts, and holds laboratory and office facilities in San Diego, California. Its operational presence and research efforts are located within the United States. As a development-stage entity, it operates in the biopharmaceutical sector without commercialized products.

Summary of the business section of Rapport Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Rapport Therapeutics, Inc.
Headquarters
Boston, MA
Address
99 High Street, Suite 2100 02110
Phone
(857) 321-8020
Employees
84, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
RAPP
Exchange
Nasdaq
IPO date
Jun 7, 2024
Shares outstanding
48M, Aug 3, 2026
Public float
$275.84M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
2012593
CUSIP
75383L102
ISIN
US75383L1026
FIGI
BBG01FRNQ4P1
Share class FIGI
BBG01FRNQ4V4
EIN
88-0724208

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Abraham CeesayChief Executive Officer, Director552,493
Troy A. IgnelziChief Financial Officer15,500
Cheryl GaultChief Operating Officer139,914
Krishnaswamy YeleswaramChief Development Officer212,063
David BredtChief Scientific Officer393,075
Jeffrey SevignyChief Medical Officer–
Trv Gp V, LlcDirector–
Third Rock Ventures VI, L.P.Director7,401,933
Third Rock Ventures GP VI, L.P.Director–
Trv Gp Vi, LlcDirector–
Third Rock Ventures V, L.P.Director8,678,314
Third Rock Ventures GP V, LPDirector–
James HealyDirector2,873,888
Ramiro SanchezDirector3,600
Paul M. SilvaDirector3,680
Steven M. PaulDirector555,022
Wendy B. YoungDirector13,289
John MaraganoreDirector9,411
Reid M. HuberDirector20,400
Robert J. PerezDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Abraham Ceesay
Chief Executive Officer
$652.93K$5.16M$431.06K$24.77K$6.27M-36%
Troy Ignelzi
Chief Financial Officer
$519.85K$1.71M$249.60K$25.92K$2.51M+2%
Jeffrey Sevigny
Chief Medical Officer
$561.09K$2.10M$283.78K$77.85K$3.02M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 7, 2024
Offer price
$17.00
Securities offered
8,000,000
Gross proceeds
$136.00M
Exchange
Nasdaq
Lock-up ends (est.)
Dec 4, 2024

“The initial public offering price per share is $17.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 84 full-time employees, and approximately 33 of our employees have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?